A Thermodynamic Cycle to Predict the Competitive Inhibition Outcomes of an Evolving Enzyme
Journal of Chemical Theory and Computation · 13.05.2025 · 21 (9) · 4910-4920
DOI: 10.1021/acs.jctc.5c00193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Theory and Computation, online erschienen am 23.04.2025. Verfasst von Ebru Cetin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering and Natural Sciences, Sabanci University, 34956 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Tetrahydrofolate Dehydrogenase, Thermodynamics, Escherichia coli, Trimethoprim. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering and Natural Sciences, Sabanci University, 34956 Istanbul, Türkiye.
ORCID-Profile: Ebru Cetin, Ali Rana Atilgan, Canan Atilgan
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Cetin, E., Abdizadeh, H., Atilgan, A. R., & Atilgan, C. (2025). A Thermodynamic Cycle to Predict the Competitive Inhibition Outcomes of an Evolving Enzyme. Journal of Chemical Theory and Computation, 21(9), 4910-4920. https://doi.org/10.1021/acs.jctc.5c00193
Vancouver
Cetin E, Abdizadeh H, Atilgan AR, Atilgan C. A Thermodynamic Cycle to Predict the Competitive Inhibition Outcomes of an Evolving Enzyme. Journal of Chemical Theory and Computation. 2025;21(9):4910-4920. doi:10.1021/acs.jctc.5c00193
BibTeX
@article{Cetin2025,
author = {Cetin, Ebru and Abdizadeh, Haleh and Atilgan, Ali Rana and Atilgan, Canan},
title = {A Thermodynamic Cycle to Predict the Competitive Inhibition Outcomes of an Evolving Enzyme},
journal = {Journal of Chemical Theory and Computation},
year = {2025},
volume = {21},
number = {9},
pages = {4910--4920},
doi = {10.1021/acs.jctc.5c00193}
}
EUVIMED